WILLOWBROOK, Ill., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel...
- Study met safety, tolerability, and pharmacokinetics primary endpoints - - Reductions in ALT, ProC3, and C6M suggest direct antifibrotic...
Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023SAN...
Goal of evaluating combination of novel viral immunotherapies with aim to potentiate CAR-T cell therapies in solid tumors Employs Candel’s...
COPENHAGEN, Denmark, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold...
Media Release SYDNEY, AUSTRALIA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from...
WARMINSTER, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive...
VANCOUVER, British Columbia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader...
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC – – Preclinical data...
Poster for presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics enhances understanding of SORT1 expression in...
AUSTIN, Texas, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
Complete response observed and ongoing in a patient with multiply relapsed/refractory diffuse large B cell lymphoma (DLBCL) Dual BTK degradation...
PETACH TIKVA, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company...
WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and...
Amended Bridging Pharmacokinetics Study for Autosomal Dominant Polycystic Kidney Disease – XRx-008 ProgramCALGARY, Alberta, Oct. 26, 2022 (GLOBE NEWSWIRE) --...
BEIJING, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc.(“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese...
Data Presented at the ACG Annual Meeting Demonstrates Successful Detection of Colon Entry and Topical Coverage Throughout Portion of Colon...
Leading authority on the therapeutic use of human tissues and cells Director, Predictive Oncology Inc. David S. Smith, JDEAGAN, Minn.,...
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the...